Analysis of factors associated with portal vein thrombosis in pediatric living donor liver transplant recipients

Abstract The technique of vascular reconstruction plays a major role in the outcome of living donor liver transplantation (LDLT). An increased use of vascular grafts (VG) to replace a sclerotic portal vein (PV) has become a standard technique in our group. The aim of this study is to analyze the factors associated with portal vein thrombosis (PVT) in pediatric LDLT. Retrospective analyses of 486 primary pediatric LDLT performed from Oct/1995 to May/2013. VG used for portal reconstruction included: living donor's inferior mesenteric vein (LDIMV) and ovarian vein (LDOV), recipient's internal jugular vein (RIJV), and deceased donor's iliac artery (DDIA) and vein (DDIV). A total of 34 (6.9%) patients developed PVT. The incidence of PVT dropped from 10% to 2%; overall utilization of VG increased from 3.5% to 37.1%. After multivariate analysis, only the use of VG remained as an independent risk factor for the occurrence of PVT (HR: 7.2, 95% CI: 2.8 to 18.7, P
Source: Liver Transplantation - Category: Transplant Surgery Authors: Tags: Original Article Source Type: research

Related Links:

Publication date: Available online 23 May 2020Source: Journal of Pediatric Surgery Case ReportsAuthor(s): Tri Hening Rahayatri, Harsya Dwindaru Gunardi, Rusdah Binti Muhammad Amin, Damayanti Sekarsari, Marini Stephanie, Sastiono Soedibyo, Seisuke Sakamoto, Mureo Kasahara
Source: Journal of Pediatric Surgery Case Reports - Category: Surgery Source Type: research
Conclusions. The majority of HEHE recipients receive exception points at a universal approval rate allowing prompt access to deceased donor LT.
Source: Transplantation - Category: Transplant Surgery Tags: Original Clinical Science—Liver Source Type: research
Publication date: Available online 15 May 2020Source: International Journal of Surgery Case ReportsAuthor(s): Damiano Patrono, Sara Salomone, Carla Guarnaccia, Francesco Tandoi, Francesco Lupo, Paolo Fonio, Renato Romagnoli
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infections are common and are associated with a variety of liver manifestations. EBV and CMV infections, in immunocompetent hosts, commonly manifest as acute hepatitis, with severity varying from asymptomatic, self-limited icteric hepatitis to acute liver failure. Atypical manifestations, such as cholestasis, chronic hepatitis, precipitation of acute-on-chronic liver failure, and autoimmune hepatitis, are reported with EBV infection, whereas cholestasis, portal vein thrombosis, and Budd-Chiari syndrome are reported with CMV infection. In the setting of liver transplantatio...
Source: Gastroenterology Clinics of North America - Category: Gastroenterology Authors: Source Type: research
Abstract ABO-incompatible (ABO-I) liver transplantation (LT) has been limited due to the increased rate of complications, including severe cellular and antibody-mediated rejection, hepatic necrosis, hepatic artery thrombosis, and biliary complications. However, several strategies for reducing preformed anti-donor ABO antibodies and B cell desensitization have improved the outcomes of ABO-I LT. As a result, ABOI LT has become a routine procedure and is a feasible option in countries with scarce deceased-organ donation or in cases without an available compatible organ donor. In this review, we describe past and pres...
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research
We present current data in cirrhosis patients regarding the treatment of portal vein and peripheral deep vein thrombosis and prophylactic strategies for peripheral thrombotic disease as well as for cirrhosis patients with co-existent atrial fibrillation. We also present very provocative data on prophylaxis of portal vein thrombosis in patients with underlying liver disease. The latter, if confirmed with blinded prospective study, could have an impact on chronic liver failure and the need for liver transplantation.
Source: Current Hepatitis Reports - Category: Infectious Diseases Source Type: research
In 2001, a Statement was published that described indications for intestinal transplantation in patients with intestinal failure expected to require parenteral nutrition indefinitely. Since 2001, advances in the management of intestinal failure including transplantation and patient survival, both on extended parenteral nutrition and after transplantation, have improved, leading to a reduction in the number of intestinal transplants worldwide from a peak of 270 per year in 2008 to 149 per year in 2017. These changes suggest that the original 2001 Statement requires reassessment. All patients with permanent intestinal failur...
Source: Transplantation - Category: Transplant Surgery Tags: Reviews Source Type: research
AbstractAtrial fibrillation (AF) and venous thromboembolism (VTE) are highly prevalent and relevant healthcare issues. Direct oral anticoagulants (DOACs) are now the first-choice for anticoagulant treatment of these conditions displaying a better efficacy/safety profile than vitamin-K antagonists, mainly due to significantly reduced risk of major bleeding, especially of intracranial haemorrhage. Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in developed countries showing a continuously growing prevalence. Nonalcoholic steatohepatitis (NASH), its evolutive form, will be the leading cause for live...
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 8 April 2020Source: Hepatobiliary &Pancreatic Diseases InternationalAuthor(s): Z. Yang, F.Z. Luo, S. Wang, J. Lerut, L. Zhuang, Q.-Y. Li, X. Xu, S.-S. Zheng
Source: Hepatobiliary and Pancreatic Diseases International - Category: Gastroenterology Source Type: research
ConclusionsLiver transplantation and combined liver –kidney transplantation appears to benefit some patients with PA or MMA, respectively, but this approach does not provide complete correction of the metabolic defect and some patients remain at risk from disease-related and transplantation-related complications, including death. Thus, all treatmen t avenues should be exhausted before consideration of organ transplantation and the benefits of this approach must be weighed against the risk of perioperative complications on an individual basis.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Liver | Liver Transplant | Ovaries | Pediatrics | Study | Thrombosis | Transplant Surgery | Transplants | Urology & Nephrology